Users Coming Off Slimming Jabs Put On Pounds Four Times Faster Compared to Those on Conventional Diets

A recent study reveals that patients who stop using popular slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end traditional lifestyle plans.

Findings released in a leading health publication demonstrates that while overweight people can lose a large proportion of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"Users buying such treatments need to be cognizant of the potential of quick rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.

This pace of recovery suggests a return to pre-treatment weight within about a year and a half.

Analyzing Approaches

The research, which reviewed dozens of studies involving thousands of participants, compared the outcomes of the injectable medications with other pills.

Scientists point out that individuals who shed pounds through dieting usually have a less rapid creep back—approximately 100 grams monthly—once they finish.

Explaining the Fast Regain

Nutrition scientists believe the way of the injections accounts for the amplified regain.

GLP-1 drugs copy a body's own chemical called GLP-1, which moderates appetite.

"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.

"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making overeating much more probable."

A Chronic Condition?

Health authorities advise the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.

Professionals contend that, given the significant potential of weight regain, the therapy should be considered life-long.

This perspective is supported by drug manufacturers, who note that the findings "underscore the chronic character of obesity," similar to managing conditions like high blood pressure.

User Accounts

Users who have stopped the jabs explain a intense resurgence of hunger.

"I experienced something flipping and you're instantly starving," recalled one woman.

This difficulty is worsened if users have not established lasting dietary or behavioural modifications during therapy.

Growing Adoption

Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.

• Adoption is greater among females than males.
• The middle-aged demographic shows the highest level of interest.
• A large proportion obtain the drugs through private healthcare rather than the NHS.

Finally, researchers emphasize that while these medications are effective tools for shedding pounds, they are not a standalone fix and long-term success hinges on ongoing behavioural support.